Cargando…

Improved survival of patients with hypermutation in uterine serous carcinoma

• Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. • Mutations in DNA polymerase ε gene (POLE) are detected in a subset of USC and confer a strong mutator phenotype. • USC patients diagnosed with POLE mutations experience a significantly better prognosis.

Detalles Bibliográficos
Autores principales:	Santin, Alessandro D., Bellone, Stefania, Centritto, Floriana, Schlessinger, Joseph, Lifton, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442647/ https://www.ncbi.nlm.nih.gov/pubmed/26076146 http://dx.doi.org/10.1016/j.gore.2015.01.005

Ejemplares similares

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
por: Bellone, Stefania, et al.
Publicado: (2023)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum
por: Gershenson, David M, et al.
Publicado: (2015)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

Stage III uterine serous carcinoma: modern trends in multimodality treatment
por: Li, Jessie Y., et al.
Publicado: (2020)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
por: Shukla, Sachet A., et al.
Publicado: (2016)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
por: Santin, Alessandro D., et al.
Publicado: (2020)

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
por: Damast, Shari, et al.
Publicado: (2015)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Pathogenesis and Clinical Management of Uterine Serous Carcinoma
por: Zhang, Li, et al.
Publicado: (2020)

Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer
por: Arden, Jessica D., et al.
Publicado: (2020)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
por: Shimizu, Maho, et al.
Publicado: (2021)

Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011)

Papillary Serous Carcinoma of the Uterine Cervix with Lung Metastasis
por: Khan, Maliha, et al.
Publicado: (2014)

Adrenal Metastasis from Uterine Papillary Serous Carcinoma
por: Lubana, Sandeep Singh, et al.
Publicado: (2016)

The role of omentectomy in the surgical treatment of uterine serous carcinoma
por: Chen, Ming, et al.
Publicado: (2019)

Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma
por: Casarin, Jvan, et al.
Publicado: (2020)

Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs
por: Kitade, Shoko, et al.
Publicado: (2019)

Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry
por: van der Ploeg, Phyllis, et al.
Publicado: (2021)

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

A new animal model for uterine torsion and uterine ischemia‐reperfusion studies, but not fetal hypoxia studies
por: Dogan, Halef, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p9ldusre9tji73m1v4roq8m539